Macrocyclic peptide oral drugs
Constrained cyclic peptides selected from trillion-member mRNA-display libraries and chemically tuned to survive the gut — the technology that produced enlicitide, the first oral PCSK9 inhibitor, approved in July 2026.
Also known as mRNA-display macrocycles, RaPID-derived macrocycles, enlicitide, oral macrocyclic peptides, Lipfendra, MK-0616
Approved drug — Licensed by a major regulator for human use, with phase-3 trial data behind it.
Enlicitide has a phase 3 programme, CORALreef, spanning more than 19,000 participants, with placebo-adjusted LDL-C reductions of roughly 56-60% at 24 weeks, and received FDA approval on 16 July 2026. Cardiovascular outcomes data from CORALreef Outcomes are still maturing, so the hard endpoint benefit is inferred from LDL-lowering rather than demonstrated. The broader macrocycle platform beyond enlicitide remains mostly preclinical.
How it works
The enabling technology is mRNA display — specifically the RaPID system, which uses flexizyme-reprogrammed translation to build libraries of 10^12 to 10^13 cyclic peptides containing non-proteinogenic residues, then selects binders against a target in vitro. The resulting hits typically bind flat protein-protein interfaces that resist small-molecule chemistry. Getting them oral is a separate medicinal-chemistry problem solved by cyclisation, N-methylation of backbone amides to remove hydrogen-bond donors, and intramolecular hydrogen bonding that lets the molecule adopt a compact, membrane-permeable conformation in lipid environments while remaining soluble in water. Enlicitide decanoate is the proof: a macrocyclic peptide that binds PCSK9 and blocks its interaction with the LDL receptor, delivering LDL-C reductions of roughly 56-60% placebo-adjusted at 24 weeks in the phase 3 CORALreef programme, and approved by the FDA on 16 July 2026 as Lipfendra, a once-daily 20 mg tablet. It is the first oral PCSK9 inhibitor and the first commercial validation that a macrocyclic peptide can compete with an injected monoclonal antibody on efficacy.
Targets: PCSK9 (enlicitide), Protein-protein interaction interfaces generally
Dosing
| Protocol | Dose | Frequency | Route |
|---|---|---|---|
| Enlicitide (Lipfendra) approved label dosingOne 20 mg tablet daily. Absorption of macrocyclic peptides is food-sensitive; follow the label's fasting instructions rather than improvising. | 20 mg | once daily | oral |
- · Approved 16 July 2026 for adults with primary hypercholesterolaemia including heterozygous familial hypercholesterolaemia, on top of statin therapy. This is a real prescription drug with a real label — the only member of this class you can actually obtain legitimately.
Titration
No titration — enlicitide is a fixed 20 mg once-daily dose.
Cycling
Lipid-lowering therapy is continuous and indefinite; LDL-C returns to baseline when it is stopped.
Pharmacology
- Half-life
- Enlicitide supports once-daily dosing. Half-life varies by molecule; the class trades some potency for oral exposure.
- Onset
- LDL-C reduction with enlicitide is substantially established within eight weeks and near-maximal by 24 weeks.
- Routes
- oral
- Molecule
- Synthetic macrocyclic peptide with non-natural amino acids and N-methylation, engineered for oral bioavailability
Handling
- Diluent
- Not applicable
- Lyophilised
- Not applicable — supplied as tablets stored at room temperature.
- Reconstituted
- Not applicable.
Mixing
Oral tablet. Nothing in this class is reconstituted.
Side effects
- commonGastrointestinal upset— The commonest complaint with oral peptide formulations generally.
- uncommonMuscle symptoms— Reported in the PCSK9 trials at rates broadly similar to placebo.
- rareInjection-site reactions— Not applicable to the oral route — one of the main advantages over injectable PCSK9 antibodies.
Do not use if
- Pregnancy - as with other lipid-lowering agents, cholesterol synthesis inhibition during fetal development is not something to experiment with.
- Known hypersensitivity to the formulation.
Combining it
- synergystatins — Enlicitide was studied and approved as add-on therapy on a statin background; the combination is the intended use.
What to monitor
- · Fasting lipid panel including LDL-C at baseline and roughly 8 weeks after starting.
- · Liver enzymes per standard lipid-therapy practice.
Legal status
Enlicitide (Lipfendra) is an FDA-approved prescription drug in the US as of July 2026. Other macrocyclic peptide candidates remain investigational.
References
- Merck 2025 — CORALreef Lipids phase 3 results for enlicitide decanoate (trial)
- FDA approval of Lipfendra (enlicitide), 16 July 2026 — first oral PCSK9 inhibitor (label)
- Passioura & Suga 2017 — RaPID mRNA display for macrocyclic peptide discovery (review)
Mechanism in depth
A delivery and chemistry strategy rather than a compound: cyclise a peptide and often N-methylate its backbone so it loses the hydrogen-bond donors that block membrane permeation, and it becomes orally absorbable while retaining the large binding surface that lets peptides hit protein-protein interfaces small molecules cannot. Ciclosporin is the natural proof that the chemistry works.
What usually goes wrong
Treating the category as a property that transfers. Oral bioavailability is engineered molecule by molecule and does not generalise - a macrocyclic peptide is not orally active because macrocyclic peptides can be. Most also carry strict fasting requirements that make real-world adherence harder than a tablet implies.
Receptor targets
- Varies entirely by molecule
The class is defined by its chemistry, not by a shared target
Genuinely uncertain
- Which programmes reach approval is unsettled; this is an active area rather than an established one.
- Food-effect magnitude varies enormously between molecules.